Biomarker Summary: NTRK

Review this PDF resource summarizing FDA-approved and investigational TRK inhibitors and testing platforms for NTRK fusions in multiple malignancies.
John L. Marshall, MD
Program Director
Todd M. Bauer, MD
Axel Grothey Headshot
Axel Grothey, MD
Michael J. Pishvaian, MD, PhD
David R. Spigel, MD
Format: Adobe Acrobat (.pdf)
File Size: 95 KB
Released: May 31, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Array BioPharma Inc.
Bayer HealthCare Pharmaceuticals Inc.
Blueprint Medicines
Celgene Corporation
Foundation Medicine, Inc.
Genentech
Loxo Oncology
Merck & Co., Inc.
Puma Biotechnology

Related Content

Phase II trial evaluating pemigatinib for previously treated mCRC with FGF/FGFR alterations, presented at ASCO GI 2023 and reported by Clinical Care Options (CCO)

Released: January 30, 2023

MOUNTAINEER concordance analysis between breast and gastric algorithms for HER2 testing in mCRC, presented at ASCO GI 2023 and reported by Clinical Care Options (CCO)

Released: January 30, 2023

SUNLIGHT trial of the addition of bevacizumab to third-line TAS-102 in refractory mCRC, presented at ASCO GI 2023 and reported by Clinical Care Options (CCO)

Released: January 30, 2023

Read expert insights on best practices for incorporating immune checkpoint inhibitor therapy for patients with NSCLC, from Clinical Care Options (CCO)

Julie R. Brahmer, MD
Program Director
person default Jarushka Naidoo, MB BCH BAO, MHS Zofia Piotrowska, MD, MHS
Released: January 23, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings